ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRY ARS PHARMACEUTICALS INC

Market Closed 04-04 16:00:00 EDT

12.80

-0.60

-4.48%

盘后12.70

-0.10-0.78%

19:56 EDT

High13.73	Low12.47	Vol2.80M
Open13.08	D1 Closing13.40	Amplitude9.40%
Mkt Cap1.26B	Tradable Cap607.40M	Total Shares98.12M
T/O36.04M	T/O Rate5.91%	Tradable Shares47.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":12.8,"timestamp":1743796800000,"preClose":13.4,"halted":0,"volume":2802329,"hourTrading":{"tag":"盘后","latestPrice":12.7,"preClose":12.8,"latestTime":"19:56 EDT","volume":4621,"amount":59170.36,"timestamp":1743811013155},"delay":0,"floatShares":47453121,"shares":98119804,"eps":0.079999,"marketStatus":"Market Closed","change":-0.6,"latestTime":"04-04 16:00:00 EDT","open":13.08,"high":13.73,"low":12.47,"amount":36041650.01428,"amplitude":0.09403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.079999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":13.4,"preHourTrading":{"tag":"盘前","latestPrice":13.05,"preClose":13.4,"latestTime":"09:27 EDT","volume":3756,"amount":49499.189688000006,"timestamp":1743773270042},"postHourTrading":{"tag":"盘后","latestPrice":12.7,"preClose":12.8,"latestTime":"19:56 EDT","volume":4621,"amount":59170.36,"timestamp":1743811013155},"volumeRatio":1.6218670301943654,"impliedVol":0.8791,"impliedVolPercentile":0.7291},"requestUrl":"/m/hq/s/SPRY","defaultTab":"news","newsList":[{"id":"2524669258","title":"High Insider Ownership Growth Stocks To Know In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524669258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524669258?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:06","pubTimestamp":1743678379,"startTime":"0","endTime":"0","summary":"As the U.S. market navigates through a period of volatility fueled by recent tariff announcements, investors are keeping a keen eye on companies that can withstand economic headwinds. In this environment, growth stocks with high insider ownership often stand out as they suggest strong confidence from those closest to the company, potentially offering resilience and alignment with shareholder interests.Top 10 Growth Companies With High Insider Ownership In The United States. Underneath we present a selection of stocks filtered out by our screen.Overview: Joint Stock Company Kaspi.kz, with a market cap of $17.92 billion, offers payments, marketplace, and fintech solutions for consumers and merchants in Kazakhstan, Azerbaijan, and Ukraine.Operations: The company's revenue segments consist of Fintech at 1.28 billion KZT, Payments at 587.10 million KZT, and Marketplace at 732.94 million KZT.Kaspi.kz's earnings are expected to grow at 15.8% annually, surpassing the US market","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-insider-ownership-growth-stocks-110619013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2065170008.USD","TBBB","BK4196","BK4613","LU1720051108.HKD","BK4097","BK4139","BK4113","LU2065169927.USD","LU1548497426.USD","BK4588","LU2357305700.SGD","LU1720051017.SGD","LU2065171311.SGD","MNDY","KSPI","BK4539","SPRY","LU2065171402.SGD"],"gpt_icon":1},{"id":"1179611170","title":"Stock Track | ARS Pharmaceuticals Plummets 5% as Analysts Slash Revenue and Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1179611170","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179611170?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 00:30","pubTimestamp":1743006628,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc.  saw its stock plummet 5.02% during intraday trading on Wednesday, following a series of downgraded forecasts from analysts. The sharp decline comes as market experts paint a gloomy picture for the company's near-term financial performance.According to the latest analyst reports, ARS Pharmaceuticals is facing significant headwinds in its revenue and earnings projections. The consensus forecast for 2025 revenues has been drastically reduced from US$125 million to US$83 mi","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1103304234","title":"Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1103304234","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103304234?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 00:30","pubTimestamp":1743006625,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc.  saw its stock plummet 5.02% during Wednesday's intraday trading session, following a series of analyst downgrades that have raised concerns about the company's future performance. The sharp decline comes as a stark contrast to the stock's recent 14% gain over the past week.Analysts have significantly cut their revenue and earnings forecasts for ARS Pharmaceuticals in 2025. The consensus revenue estimate has been reduced from $125 million to $83 million, representing a 6","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2522874286","title":"ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522874286","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522874286?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:16","pubTimestamp":1742984206,"startTime":"0","endTime":"0","summary":"The latest analyst coverage could presage a bad day for ARS Pharmaceuticals, Inc. , with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share  forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Surprisingly the share price has been buoyant, rising 14% to US$13.15 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-nasdaq-spry-101646429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","PSQ","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","USJW.SI","NVIW.SI","NQmain","BK4585","MNQmain","TQQQ","USAW.SI","TSYW.SI","SPRY","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","BK4139","QID","IE00B3QW5Z07.USD","QLD","IE00BKPKM429.USD","SQQQ",".IXIC","BK4112"],"gpt_icon":1},{"id":"1168497902","title":"Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike","url":"https://stock-news.laohu8.com/highlight/detail?id=1168497902","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168497902?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:10","pubTimestamp":1742818218,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.Raymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.The target price hike suggests that Raymond James analysts ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2521274121","title":"ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $32 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2521274121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521274121?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:29","pubTimestamp":1742815793,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q7159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1131332685","title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% Following Q4 Earnings and Analyst Price Target Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1131332685","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131332685?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:33","pubTimestamp":1742563985,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock plummet 5.59% in pre-market trading on Friday, following the company's fourth quarter and full year 2024 earnings release and a subsequent analyst price target cut.The decline comes as Leerink Partners lowered their price target on ARS Pharmaceuticals from $27 to $26, signaling some caution despite the company's progress with its flagship product, neffy, a needle-free epinephrine nasal spray. This adjustment in valuation likely contributed to investor conce","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1132725662","title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=1132725662","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132725662?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:32","pubTimestamp":1742563968,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market ex","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2521400448","title":"ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400448","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400448?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:38","pubTimestamp":1742557093,"startTime":"0","endTime":"0","summary":"Profit margin: 9.0% . The move to profitability was driven by higher revenue.We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGM:SPRY Earnings and Revenue Growth March 21st 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates significantly. Earnings per share  also surpassed analyst estimates.Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 21% from a week ago.While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of ARS Pharmaceuticals' balance sheet and an in-depth analysis of the company's financial position.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-full-2024-earnings-113813678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2521215534","title":"ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521215534","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521215534?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 15:03","pubTimestamp":1742540588,"startTime":"0","endTime":"0","summary":"Net Product Revenue: $7.3 million for the full year 2024, with $6.7 million in the fourth quarter.Total Revenue: $89.1 million for the full year 2024, including collaboration and supply agreement revenues.Collaboration Revenue: $73.5 million from ALK and $6 million from a Japanese licensing partner in Q4 2024.R&D Expenses: $19.6 million for the full year 2024.SG&A Expenses: $71.7 million for the full year 2024.Net Income: $49.9 million for Q4 2024, $8 million for the full year 2024.Cash Position: $314 million in cash, cash equivalents, and short-term investments at year-end 2024.Operating Expenses Forecast: $200 million to $210 million for the full year 2025, excluding certain costs.GuruFocus has detected 4 Warning Signs with SPRY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.ARS Pharmaceuticals Inc  successfully launched neffy 2 milligrams in the United States and secured FDA approval for the 1 milligram dose for children, represen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-q4-070308778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2521944225","title":"Q4 2024 ARS Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2521944225","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521944225?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 12:40","pubTimestamp":1742532039,"startTime":"0","endTime":"0","summary":"Justin Chakma; Chief Business Officer; ARS Pharmaceuticals Inc. Richard Lowenthal; President, Chief Executive Officer, Co-Founder, Director; ARS Pharmaceuticals Inc. Thank you, Justin, and thank you to everyone dialing in today. The past six months have been extremely productive for ARS. Since September, we have successfully launched neffy 2 milligrams in the United States and secured FDA approval for the 1 milligram neffy dose for patients weighing 15 kilograms to less than 30 kilograms. The population of children at this lower weight range that will use neffy 1 milligram represents 23% of the current auto-injector market. ARS has also made significant strides in payer coverage, with over 51% commercially insured able to get neffy without a prior authorization as of April 1, and we anticipate over 80% with our prior authorization by early this summer with the addition of neffy to the Caremark formulary. Our commercial execution has established a strong foundation of health care provid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-ars-pharmaceuticals-inc-044039579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CI","CVS","SPRY"],"gpt_icon":0},{"id":"2520466052","title":"BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2520466052","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520466052?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:56","pubTimestamp":1742486202,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli LillyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q318Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNNE","QXO","EPAM","EYEN","LENZ","SCVL","RIVN","LU1023057109.AUD","WINT","BECN","DRI","COTY","ELEV","LU0310799852.SGD","VVPR","IE00B4R5TH58.HKD","PSTV","CVNA","LU1023059063.AUD","IE00B3M56506.USD","LU0823414478.USD","KKR","ACN","LU2764262908.HKD","AKBA","OPTN","CLDX","NOVA","LU0068578508.USD","YRD","JBL","LU2360106947.USD","BK4600","PRA","BGSF","FIVE","IE00B5949003.HKD","LLY","MCHP","SAG","SPRY","ASO","STZ","BK4077","BKKT","ZK","PII","LU2764263039.SGD"],"gpt_icon":1},{"id":"2520457996","title":"ARS Pharma Shares Climb on Surprise 4Q Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2520457996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520457996?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 22:03","pubTimestamp":1742479380,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals were sharply higher after the biopharmaceutical company posted earnings and revenue that came in well above Wall Street views.The stock was up 22% at $14.22 in early trading. That puts it at a gain of more than 60% over the past 12 months.The San Diego-based biopharmaceutical company, whose main product is an emergency nasal spray for severe allergic reactions, on Thursday reported a profit of $49.9 million, or 48 cents a share.Analysts were anticipating a loss of 24 cents per share, and a year earlier the company said it lost $7.2 million.Revenue for the quarter came to $86.6 million, surpassing analyst expectations for $5.7 million.ARS said its neffy nasal-spray product brought in $7.3 million in net revenue from its late-September launch through the end of the year.The company added that, with $314 million in cash, cash equivalents and short-term investments as of Dec. 31, it continues to expect its financial position to support its operating plans for ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2520522174","title":"BUZZ-ARS Pharma rises on surprise Q4 profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522174?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:53","pubTimestamp":1742478789,"startTime":"0","endTime":"0","summary":"BUZZ-ARS Pharma rises on surprise Q4 profit** Drug developer ARS Pharmaceuticals' SPRY.O shares rise 18.8% to $13.84** Co reports Q4 net income of $49.9 million vs. loss estimate of $14.4 million, according to data compiled by LSEG** Co posts Q4 revenue of $86.6 million, beating analysts' estimates of $15.8 million** Profit boosted by partnership revenue from drug developer ALK-Abelló to commercialise allergic reaction nasal spray, neffy, in Europe, Canada and outside of U.S.** SPRY received a non-refundable, upfront cash payment of $145 million from ALK and, of the total cash payment, $73.5 million was included in SPRY's Q4 revenue** Up to last close, SPRY had risen 37.7% in the past 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q30VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1167596754","title":"Stock Track | ARS Pharmaceuticals Soars 20% on Stellar Q4 Results and Strong 2024 Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1167596754","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167596754?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:39","pubTimestamp":1742477968,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  are skyrocketing 20.34% in pre-market trading on Thursday following the release of the company's fourth quarter and full-year 2024 financial results, which dramatically exceeded analyst expectations.The biopharmaceutical company, known for its needle-free epinephrine nasal spray neffy, reported a quarterly earnings per share of $0.48, significantly outperforming the analyst consensus estimate of a $0.14 loss. This represents a substantial improvement from the $","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2520454290","title":"ARS Pharmaceuticals Shares up 11.5% After Q4 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2520454290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520454290?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:32","pubTimestamp":1742477535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q313T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2520451255","title":"Sector Update: Health Care Stocks Decline Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2520451255","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520451255?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:13","pubTimestamp":1742476436,"startTime":"0","endTime":"0","summary":"Health care stocks leaned lower premarket Thursday as the Health Care Select Sector SPDR Fund  fell by 0.2% and the iShares Biotechnology ETF  was down 0.1% recently.ARS Pharmaceuticals  shares advanced by over 4% after the company reported that it swung to 2024 earnings as revenue surged during the year.Elevation Oncology  shares were almost 36% lower after the company said it is dropping the development of EO-3021, an antibody-drug conjugate for the potential treatment of advanced, unresectable, or metastatic gastric and gastroesophageal junction cancers.OptiNose  shares were up more than 58% after the company overnight said it agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPTN","BK4139","BK4581","BK4007","SPRY","XLV","ELEV","IBB","BK4585","BK4539","BK4588"],"gpt_icon":0},{"id":"2520458570","title":"ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458570?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:34","pubTimestamp":1742470475,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  reported Q4 net income Thursday of $0.48 per diluted share.Three analysts surveyed by FactSet expected a loss of $0.04.Revenue for the quarter ended Dec. 31 was $86.6 million.For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.Four analysts polled by FactSet expected a loss of $0.52.Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.Shares of the company were up more than 7% in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY"],"gpt_icon":0},{"id":"1127753298","title":"Stock Track | ARS Pharmaceuticals Soars 9.44% Pre-Market on Strong Q4 Earnings, Positive Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1127753298","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127753298?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:18","pubTimestamp":1742469524,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  shares surged 9.44% in pre-market trading on Thursday following the release of its fourth quarter and full-year 2024 financial results, which significantly exceeded analyst expectations.The strong financial performance was bolstered by several positive business updates. ARS Pharmaceuticals reported $7.3 million in total neffy U.S. net product revenue for 2024 since its launch in late September. The company also announced FDA approval for neffy 1 mg for younger children, ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2520543708","title":"ARS Pharmaceuticals up 5.8% Premarket After Q4 Results Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2520543708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520543708?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:10","pubTimestamp":1742469028,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q30SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":0.0248},{"period":"1month","weight":0.1776},{"period":"3month","weight":0.1439},{"period":"6month","weight":-0.098},{"period":"1year","weight":0.3431},{"period":"ytd","weight":0.2133}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.029887},{"month":2,"riseRate":0.6,"avgChangeRate":0.08605},{"month":3,"riseRate":0.4,"avgChangeRate":-0.024933},{"month":4,"riseRate":0.2,"avgChangeRate":-0.10243},{"month":5,"riseRate":0.75,"avgChangeRate":0.018154},{"month":6,"riseRate":0.5,"avgChangeRate":0.064481},{"month":7,"riseRate":0.75,"avgChangeRate":0.142893},{"month":8,"riseRate":0.5,"avgChangeRate":-0.015111},{"month":9,"riseRate":0.25,"avgChangeRate":-0.231382},{"month":10,"riseRate":0.5,"avgChangeRate":0.000594},{"month":11,"riseRate":0.25,"avgChangeRate":0.038319},{"month":12,"riseRate":0.5,"avgChangeRate":0.045103}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}